SCHEMBL30937201

SCHEMBL30937201

CN(C(=O)C12CC(O)(C1)C2)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.40
SLC6A3 Q01959 5/20 0.40
GPBAR1 Q8TDU6 1/20 0.39
EPHX2 P34913 2/20 0.39
HCRTR2 O43614 1/20 0.37
MMP2 P08253 2/20 0.37
MMP9 P14780 2/20 0.37
MMP8 P22894 2/20 0.37
MMP13 P45452 1/20 0.37
LIPE Q05469 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30937156 0.83 GPBAR1 (0.38) SLC6A4SLC6A3GPBAR1EPHX2MMP2
SCHEMBL30937116 0.79 GAA (0.37) GPBAR1
SCHEMBL1147154 0.77 MMP3 (0.43) SLC6A4SLC6A3GPBAR1EPHX2MMP2
SCHEMBL30937015 0.77 ALDH1A1 (0.41) GPBAR1L3MBTL1
SCHEMBL30936910 0.76 ALDH1A1 (0.37) GPBAR1TDP1L3MBTL1
SCHEMBL30937041 0.76 ALDH1A1 (0.39) GPBAR1LIPETDP1L3MBTL1
SCHEMBL30937191 0.76 KMT2A (0.41) L3MBTL1
SCHEMBL1875890 0.76 SERPINE1 (0.49) SLC6A4GPBAR1EPHX2LIPEHDAC3
SCHEMBL15504635 0.76 MAPT (0.57) GPBAR1EPHX2LIPEHDAC3HDAC4
SCHEMBL5535914 0.74 GPBAR1 (0.46) SLC6A4GPBAR1EPHX2HCRTR2LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed